Advances in the treatment of secondary CNS lymphoma

Journal of Clinical Oncology

Volumn 33, Issue 33, 2015, Pages 3851-3853

  Schmitz, Norbert ^a   Wu, Huei Shan ^a  

^a DEPARTMENT OF CARDIOLOGY   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

BLEOMYCIN; BUSULFAN; CARMUSTINE; CYCLOPHOSPHAMIDE; CYTARABINE; DEXAMETHASONE; DOXORUBICIN; ETOPOSIDE; IFOSFAMIDE; METHOTREXATE; PREDNISONE; PROCARBAZINE; RITUXIMAB; THIOTEPA; VINDESINE; ANTIMETABOLITE; ANTINEOPLASTIC AGENT;

AUTOLOGOUS HEMATOPOIETIC STEM CELL TRANSPLANTATION; BLOOD BRAIN BARRIER; CANCER CHEMOTHERAPY; CANCER RADIOTHERAPY; CANCER RECURRENCE; EDITORIAL; HUMAN; INDUCTION CHEMOTHERAPY; LYMPHOMA; MONOTHERAPY; PHASE 2 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; RETROSPECTIVE STUDY; SECONDARY CENTRAL NERVOUS SYSTEM LYMPHOMA; SYSTEMIC THERAPY; CENTRAL NERVOUS SYSTEM NEOPLASMS; LYMPHOMA, B-CELL; PROCEDURES; STEM CELL TRANSPLANTATION;

ANTIMETABOLITES; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CENTRAL NERVOUS SYSTEM NEOPLASMS; HUMANS; LYMPHOMA, B-CELL; STEM CELL TRANSPLANTATION;

EID: 84948452005     PISSN: 0732183X     EISSN: 15277755     Source Type: Journal    
DOI: 10.1200/JCO.2015.63.1143     Document Type: Editorial

References (32)

1. Schmitz N, Zeynalova S, Nickelsen M, et al: A new prognostic model to assess the risk of CNS disease in patients with aggressive B-cell lymphoma. Hematol Oncol 31:047a, 2013 (abstr)
2. Savage KJ, Zeynalova S, Kansara R, et al: Validation of a prognostic model to assess the risk of CNS disease in patients with aggressive B-cell lymphoma. Blood 124:394a, 2014 (abstr)
3. Tomita N, Yokoyama M, Yamamoto W, et al: Central nervous system event in patients with diffuse large B-cell lymphoma in the rituximab era. Cancer Sci 103:245-251, 2012
4. Schmitz N, Zeynalova S, Glass B, et al: CNS disease in younger patients with aggressive B-cell lymphoma: An analysis of patients treated on the Mabthera International Trial and trials of the German High-Grade Non-Hodgkin Lymphoma Study Group. Ann Oncol 23:1267-1273, 2012
5. Boehme V, Schmitz N, Zeynalova S, et al: CNS events in elderly patients with aggressive lymphoma treated with modern chemotherapy (CHOP-14) with or without rituximab: An analysis of patients treated in the RICOVER-60 trial of the German High-Grade Non-Hodgkin Lymphoma Study Group (DSHNHL). Blood 113:3896-3902, 2009
6. Tai WM, Chung J, Tang PL, et al: Central nervous system (CNS) relapse in diffuse large B cell lymphoma (DLBCL): Pre-and post-rituximab. Ann Hematol 90:809-818, 2011
7. Villa D, Connors JM, Shenkier TN, et al: Incidence and risk factors for central nervous system relapse in patients with diffuse large B-cell lymphoma: The impact of the addition of rituximab to CHOP chemotherapy. Ann Oncol 21:1046-1052, 2010
8. Shimazu Y, Notohara K, Ueda Y: Diffuse large B-cell lymphoma with central nervous system relapse: Prognosis and risk factors according to retrospective analysis from a single-center experience. Int J Hematol 89:577-583, 2009
9. Guirguis HR, Cheung MC, Mahrous M, et al: Impact of central nervous system (CNS) prophylaxis on the incidence and risk factors for CNS relapse in patients with diffuse large B-cell lymphoma treated in the rituximab era: A single center experience and review of the literature. Br J Haematol 159:39-49, 2012
10. Yamamoto W, Tomita N, Watanabe R, et al: Central nervous system involvement in diffuse large B-cell lymphoma. Eur J Haematol 85:6-10, 2010
11. Chihara D, Oki Y, Matsuo K, et al: Incidence and risk factors for central nervous system relapse in patients with diffuse large B-cell lymphoma: Analyses with competing risk regression model. Leuk Lymphoma 52:2270-2275, 2011
12. Feugier P, Virion JM, Tilly H, et al: Incidence and risk factors for central nervous system occurrence in elderly patients with diffuse large-B-cell lymphoma: Influence of rituximab. Ann Oncol 15:129-133, 2004
13. Savage KJ, Sehn LH, Villa D, et al: The impact of concurrent MYC BCL2 protein expression on the risk of secondary central nervous system relapse in diffuse large B-cell lymphoma (DLBCL). Blood 495a, 2014. https://ash.confex .com/ash/2014/webprogram/Paper71014.html
14. Bernstein SH, Unger JM, Leblanc M, et al: Natural history of CNS relapse in patients with aggressive Non-Hodgkin's lymphoma: A 20-year follow-up analysis of SWOG 8516 - The Southwest Oncology Group. J Clin Oncol 27:114-119, 2009
15. Hegde U, Filie A, Little RF, et al: High incidence of occult leptomeningeal disease detected by flow cytometry in newly diagnosed aggressive B-cell lymphomas at risk for central nervous system involvement: The role of flow cytometry versus cytology. Blood 105:496-502, 2005
16. Quijano S, López A, Manuel Sancho J, et al: Identification of leptomeningeal disease in aggressive B-cell non-Hodgkin's lymphoma: Improved sensitivity of flow cytometry. J Clin Oncol 27:1462-1469, 2009
17. Kumar A, Vanderplas A, LaCasce AS, et al: Lack of benefit of central nervous system prophylaxis for diffuse large B-cell lymphoma in the rituximab era: Findings from a large national database. Cancer 118:2944-2951, 2012
18. Tomita N, Takasaki H, Ishiyama Y, et al: Intrathecal methotrexate prophylaxis and central nervous system relapse in diffuse large B-cell lymphoma patients following R-CHOP. Leuk Lymphoma 10:1-20, 2014
19. Arkenau HT, Chong G, Cunningham D, et al: The role of intrathecal chemotherapy prophylaxis in patients with diffuse large B-cell lymphoma. Ann Oncol 18:541-545, 2007
20. Holte H, Leppä S, Björkholm M, et al: Dose-densified chemoimmunotherapy followed by systemic central nervous system prophylaxis for younger high-risk diffuse large B-cell/follicular grade 3 lymphoma patients: Results of a phase II Nordic Lymphoma Group study. Ann Oncol 24:1385-1392, 2013
21. Tilly H, Lepage E, Coiffier B, et al: Intensive conventional chemotherapy (ACVBP regimen) compared with standard CHOP for poor-prognosis aggressive non-Hodgkin lymphoma. Blood 102:4284-4289, 2003
22. Schultz C, Scott C, Sherman W, et al: Preirradiation chemotherapy with cyclophosphamide, doxorubicin, vincristine, and dexamethasone for primary CNS lymphomas: Initial report of Radiation Therapy Oncology Group protocol 88-06. J Clin Oncol 14:556-564, 1996
23. O'Neill BP, O'Fallon JR, Earle JD, et al: Primary central nervous system non-Hodgkin's lymphoma: Survival advantages with combined initial therapy? Int J Radiat Oncol Biol Phys 33:663-673, 1995
24. DeAngelis LM, Yahalom J, Thaler HT, et al: Combined modality therapy for primary CNS lymphoma. J Clin Oncol 10:635-643, 1992
25. Ferreri AJ, Reni M, Foppoli M, et al: High-dose cytarabine plus high-dose methotrexate versus high-dose methotrexate alone in patients with primary CNS lymphoma: A randomized phase 2 trial. Lancet 374:1512-1520, 2009
26. Soussain C, Hoang-Xuan K, Taillandier L, et al: Intensive chemotherapy followed by hematopoietic stem-cell rescue for refractory and recurrent primary CNS and intraocular lymphoma: Société Française de Greffe de Moëlle Osseuse-Thérapie Cellulaire. J Clin Oncol 26:2512-2518, 2008
27. Korfel A, Elter T, Thiel E, et al: Phase II study of central nervous system (CNS)-directed chemotherapy including high-dose chemotherapy with autologous stem cell transplantation for CNS relapse of aggressive lymphomas. Haematologica 98:364-370, 2013
28. Omuro A, Correa DD, DeAngelis LM, et al: R-MPV followed by high-dose chemotherapy with TBC and autologous stem-cell transplant for newly diagnosed primary CNS lymphoma. Blood 125:1403-1410, 2015
29. Doorduyn JK, van Imhoff GW, van Montfort KCAGM, et al: Treatment of secondary central nervous system lymphoma with intrathecal rituximab, high dose methotrexate and R-DHAP, followed by autologous stem cell transplantation: A phase II HOVON study. Blood 306a, 2012. https://ash.confex.com/ash/2012/webprogram/Paper51025.html
30. Illerhaus G, Müller F, Feuerhake F, et al: High-dose chemotherapy and autologous stem-cell transplantation without consolidating radiotherapy as firstline treatment for primary lymphoma of the central nervous system. Haematologica 93:147-148, 2008
31. Rubenstein JL, Combs D, Rosenberg J, et al: Rituximab in CNS lymphoma: Targeting the leptomeningeal compartment. Blood 101:466-468, 2003
32. Ferreri AJM, Donadoni G, Cabras MG, et al: High doses of antimetabolites followed by high-dose sequential chemoimmunotherapy and autologous stemcell transplantation in patients with systemic B-cell lymphoma and secondary CNS involvement: Final results of a multicenter phase II trial. J Clin Oncol 33:3903-3910, 2015